Skip to main content
. 2023 Feb 22;18:33. doi: 10.1186/s13023-023-02631-7

Table 1.

Items of the DELPHI-based exercise for the management of sequelae in epidermal necrolysis

Disagreement index (DI)* Median
Items the panel agreed were ‘appropriate’
 General recommendations
  A follow-up control SHOULD be performed 1–2 months after discharge from the hospital and regularly thereafter as needed 0 9
  Professionals involved
  Patients SHOULD be managed by a multidisciplinary team 0 9
  The DERMATOLOGIST SHOULD lead in the management of follow-up 0.531 8
  An OPHTHALMOLOGIST SHOULD be involved in case of ocular involvement 0 9
  Support by a PSYCHIATRIST and/or PSYCHOLOGIST SHOULD be offered 0.132 9
  A DENTIST and/or a STOMATOLOGIST SHOULD be involved in case of chronic oral mucosal involvement 0.132 9
  An ENT specialist SHOULD be involved after discharge if there was nasopharyngeal and/or laryngeal involvement in the acute phase 0.132 9
  A UROLOGIST SHOULD be involved in cases of severe genital involvement, where a risk of urethral synechiae/strictures exists 0 9
  A GYNECOLOGIST SHOULD be involved in case of severe genital involvement, where a risk of vaginal synechiae/strictures exists 0 9
  A PULMONOLOGIST SHOULD be involved after discharge if there was pulmonary involvement in the acute phase 0.132 9
  A SOCIAL WORKER SHOULD be involved if needed 0 9
  A DIETICIAN SHOULD be involved if needed 0.292 9
Skin
  Patients SHOULD practise careful sun protection post-discharge 0 9
  Patients SHOULD apply emollients daily 0.262 9
  Laser treatment MAY be considered for hypertrophic scars 0.374 7
  Residual skin pain SHOULD be further investigated 0.292 8
  A NEUROLOGIST or a PAIN SPECIALIST SHOULD be involved in patients with chronic skin pain 0.132 9
 Oral mucosa and teeth
  Patients SHOULD receive specific instructions for dental health 0.262 9
  Patients who had oral mucosa involvement SHOULD have regular dental check-ups 0.132 9
  Specific therapy SHOULD be implemented in patients with xerostomia 0.019 9
  Saliva substitutes SHOULD be used in patients with xerostomia 0.132 9
  Topical sialagogues MAY be considered in patients with xerostomia 0.292 8
 Eyes
  Patients SHOULD undergo a complete ophthalmological examination as often as needed 0 9
  An OPHTHALMOLOGIST SHOULD guide the medical treatment of ocular symptoms 0 9
  A combination of artificial tears without preservatives and topical vitamin A SHOULD be used in patients with xerophthalmia 0.319 8
  The use of topical cyclosporine or other immunosuppressive agent MAY be proposed in patients with severe xerophthalmia 0.374 7
  The use of scleral lenses SHOULD be considered in patients with severe xerophthalmia and/or scarring 0.292 8
  Surgical ocular surface reconstruction SHOULD be considered as a last resort in patients with extensive scarring 0.724 7
 Genital area
  Sequelae such as vulvodynia, vulvar and vaginal synechiae SHOULD be assessed after epithelialization 0.018 9
  Topical corticosteroids SHOULD be considered in patients with vulvar and/or vaginal synechiae to reduce extensive scarring 0.292 8
  Surgical correction SHOULD be considered in cases of extensive vulvar and/or vaginal scarring 0.132 9
  Emollients SHOULD be used to avoid vulvar and vaginal dryness 0.132 9
 Mental health
  Every follow-up control SHOULD include a screening for psychological well-being 0.132 9
  This screening SHOULD include questions on the quality of sleep, mood status, anxiety, nightmares, and symptoms of depression 0 9
  A standardized tool such as hospital anxiety and depression score (HADS) MAY be helpful in the screening for psychological well-being 0.132 9
  Psychological support SHOULD be actively offered to patients with chronic disabling sequelae 0 9
  A psychological and/or psychiatric follow-up CAN help to reduce issues like post-traumatic stress disorder 0 9
  Iatrogenic psychiatric symptoms SHOULD be excluded 0.292 8
  Psychotropic drugs MAY be considered according to the psychiatrist’s evaluation 0.292 9
 Allergy workup
  A preliminary allergy card prohibiting the use of ALL suspect drugs MUST be given to the patient upon release from the hospital 0 9
  The patient MUST be clearly informed during the hospital stay about the suspect drug(s), their avoidance and cross-reactivity 0 9
  The patient’s companion/family MUST be clearly informed during the hospital stay about the suspect drug(s), their avoidance and cross-reactivity 0 9
  Prick tests SHOULD NOT be routinely performed 0.132 9
  Intradermal tests SHOULD NOT be routinely performed 0.292 9
  If available, a lymphocytic transformation test (LTT) CAN be useful in the diagnostic work-up 0.492 8
  If available, an Elispot test CAN be useful in the diagnostic work-up 0.748 7
  A drug CANNOT be excluded as culprit agent solely based on negative results of any of the allergological tests 0 9
  A definitive allergy card MUST be given to the patient after the allergy work-up 0 9
  The patient MUST be clearly informed about the drug(s) on the allergy card, their avoidance and cross-reactivity after the allergy work-up 0 9
  The general practitioner and all physicians involved in the management of the patient MUST be informed about the drug(s) on the allergy card, their avoidance and cross-reactivity after the allergy work-up 0 9
Items the panel agreed were ‘uncertain’
 Eyes
  Corneal transplantation SHOULD NOT be recommended due to the risk of clinical exacerbation 0.652 5
 Mental health
  Additional measures such as hypnosis MAY help reducing symptoms of anxiety or depression 0.652 5
 Allergy workup
  Allergological testing SHOULD be performed at least 6–8 weeks after complete re-epithelization 0.652 6
  Patch-tests SHOULD be performed for the diagnostic work-up 0.519 5
Items the panel agreed were ‘inappropriate’
 None
Items the panel disagreed
 None

*A disagreement index value greater than 1 indicates a lack of consensus; below 1 indicates a consensus